Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024

Protara Therapeutics, Inc.

Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).
Cash and marketable securities $130.7M as of Dec 31, 2021; expected to fund operations into mid-2024.
R&D expenses rose to $4.1M in Q4 (vs $3.7M prior year) and $21.1M for full year (vs $12.0M).
Phase 1 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) has commenced after FDA IND clearance.
Jathin Bandari, M.D., appointed as Chief Medical Officer in January 2022; previously Interim CMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.